Search results
Results from the WOW.Com Content Network
Terbinafine is an antifungal medication used to treat pityriasis versicolor, ... Common side effects when taken by mouth include nausea, ... Immune system problems: ...
In addition to the presence of Malassezia, genetic, environmental, hormonal, and immune-system factors are necessary for and/or modulate the expression of seborrhoeic dermatitis. [ 15 ] [ 16 ] The condition may be aggravated by illness, psychological stress, fatigue, sleep deprivation, change of season, and reduced general health.
First topical terbinafine medication (MOB-015) was launched in February 2024 in Sweden under the name Terclara. This medication recorded 76% mycological cure rate in two phase 3 studies. The topical property of this medication ensures that typical terbinafine side effects are not present (1000 times lower terbinafine levels in plasma).
Other problems are respiratory and/or immune system responses including respiratory symptoms, respiratory infections, exacerbation of asthma, and rarely hypersensitivity pneumonitis, allergic alveolitis, chronic rhinosinusitis and allergic fungal sinusitis. A person's reaction to mold depends on their sensitivity and other health conditions ...
The United States Food and Drugs Administration is warning pet owners about a common medication given to pets to treat arthritis. The F.D.A. now says that the drug Librela may be associated with ...
The side effects of oral treatment are significant and people without an infection should not take these drugs. [36] Azoles are the group of antifungals which act on the cell membrane of fungi. They inhibit the enzyme 14-alpha-sterol demethylase, a microsomal CYP, which is required for the biosynthesis of ergosterol for the cytoplasmic membrane.
The common cold is caused by more than 200 respiratory viruses, which is a lot for your immune system to try to defend against. According to the Centers for Disease Control and Prevention (CDC ...
Hints and the solution for today's Wordle on Friday, December 13.